Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs)
effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with …

Simple Summary Immunomodulatory drugs (IMiDs) are effective in the treatment of multiple
myeloma (MM) and other hematological malignancies. Cereblon (CRBN), a target of IMiDs …

Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective
treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function …

The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide, all
approved for the treatment of multiple myeloma, induce targeted ubiquitination and …

Immunomodulatory drugs (IMiDs) exert anti-myeloma activity by binding to the protein
cereblon (CRBN) and subsequently degrading IKZF1/3. Recently, their ability to recruit E3 …

Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in
many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic …

Thalidomide was first developed as a sedative around 60 years ago, but exhibited
teratogenicity, leading to serious defects such as limb deformities. Nevertheless, thalidomide …

The immunomodulatory drug (IMiD) thalidomide and its structural analogs lenalidomide and
pomalidomide are highly effective in treating clinical indications. Thalidomide binds to …

Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective
treatments for multiple myeloma and myelodysplastic syndrome with del (5q). These …

Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide show remarkable
antitumor activity in multiple myeloma (MM) via directly inhibiting MM-cell growth in the bone …